Safety of Amlodipine in Early Pregnancy

Author:

Mito Asako12,Murashima Atsuko12,Wada Yoshinao3,Miyasato‐Isoda Mai4,Kamiya Chizuko A.5,Waguri Masako3,Yoshimatsu Jun5,Yakuwa Naho1,Watanabe Omi1,Suzuki Tomo16,Arata Naoko12,Mikami Masashi7,Ito Shinya8

Affiliation:

1. Drug Information Institute in Pregnancy Tokyo Japan

2. Division of Maternal Medicine Center for Maternal‐Fetal‐Neonatal and Reproductive Medicine National Center for Child Health and Development Tokyo Japan

3. Department of Obstetric Medicine Osaka Women's and Children's Hospital Osaka Japan

4. Department of Internal Medicine (I) Osaka Medical College Osaka Japan

5. Department of Perinatology and Gynecology National Cerebral and Cardiovascular Center Osaka Japan

6. Division of Obstetrics Center for Maternal‐Fetal‐Neonatal and Reproductive Medicine National Center for Child Health and Development Tokyo Japan

7. Division of Biostatistics Clinical Research Center National Center for Child Health and Development Tokyo Japan

8. Motherisk Program Division of Clinical Pharmacology and Toxicology Department of Paediatrics The Hospital for Sick Children University of Toronto Toronto Canada

Abstract

Background Amlodipine is used for the treatment of hypertension, but reports on its use in early pregnancy are limited. Methods and Results In the present study, we recruited 231 women with chronic hypertension, including those who received amlodipine or other antihypertensives during early pregnancy, and investigated frequencies of morphologic abnormalities in their 231 offspring. Specifically, we evaluated 48 neonates exposed to amlodipine in the first trimester (amlodipine group, Group A), 54 neonates exposed to antihypertensives other than amlodipine (other antihypertensive group, Group O), and 129 neonates not exposed to antihypertensives (no‐antihypertensive group, Group N). The number of morphologic abnormalities of offspring in each group were 2 in Group A (4.2%; 95% CI , 0.51–14.25); 3 in Group O (5.6%; 95% CI , 1.16–15.39) and 6 in Group N (4.7%; 95% CI, 1.73–9.85). The odds ratio of the primary outcome comparing Group A and Group O was 0.74 (95% CI : 0.118–4.621) and Group A and Group N was 0.89 (95% CI : 0.174–4.575). Conclusions The odds of birth defects in Group A in the first trimester were not significantly different from those with or without other antihypertensives.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cardiology and Cardiovascular Medicine

Cited by 26 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3